Suicide risk modification by statin prescriptions in US Veterans with common inflammation-mediated clinical conditions- a controlled, quasi-randomized epidemiological approach
通过他汀类药物处方降低患有常见炎症介导临床病症的美国退伍军人的自杀风险——一种受控、准随机的流行病学方法
基本信息
- 批准号:10487844
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:AgeAutoimmuneAutoimmune DiseasesBipolar DisorderBloodBrainCardiovascular systemCategoriesCellsCharacteristicsClinicalCodeCognition DisordersComputerized Medical RecordCox Proportional Hazards ModelsDataDevelopmentDiagnosisDiagnosticDisease susceptibilityDoseEncephalitisEpidemicEpidemiologyEquationEvaluationFutureGenderGeneral PopulationHematologyHigh PrevalenceHistologicHospitalizationHypersensitivityImmuneImpairmentIndividualInfectionInflammationInterventionLDL Cholesterol LipoproteinsLaboratory MarkersLinkMachine LearningMeasuresMediatingMediationMedicalMedical centerMental DepressionMental HealthMental disordersMetabolicMethodologyMicrogliaModelingModificationMolecularOutcomeOxidative StressPharmaceutical PreparationsPharmacodynamicsPost-Traumatic Stress DisordersPreventionProcessProxyRandomizedRecording of previous eventsRegimenRelative RisksReportingReproducibilityResearchResearch Project GrantsRetrospective cohortRiskRisk FactorsRisk ManagementSchizophreniaSelf DirectionSeveritiesSuicideSuicide attemptSuicide preventionTestingTherapeuticTimeTraumatic Brain InjuryUnited StatesVeteransVeterans Health AdministrationViolenceVitamin D Deficiencyattenuationclinical encountercomorbiditydesigndisabilitydrug repurposingendothelial dysfunctionevidence baseexcitotoxicityhazardimmune activationimmunoregulationimprovedindexinginflammatory markermachine learning algorithmmemberneuroinflammationneuroprotectionnovelnovel strategiespharmacologicphysical conditioningprotective effectpsychologicrandomized, clinical trialsresiliencesuicidalsuicidal behaviorsuicidal morbiditysuicidal risksuicide ratesynergismtraittreatment duration
项目摘要
In addition to their metabolic and cardiovascular protective effects, statins reproducibly engage multiple
pathophysiological factors implicated in suicidal behavior - neuroinflammation, increased oxidative
stress, excitotoxicity, and endothelial dysfunction. Add-on statins have been also reported to improve
therapeutic control in physical and mental health. The Veterans’ persistent higher rates of suicide have
remained unabated challenges and, and thus, demanding new ways of understanding and engaging in
preventative efforts. The long-term objective of our group is to uncovering new modifiable targets, novel
and repurposed treatments in suicide prevention, and identifying individuals at risk who are likely to most
benefit from specific interventions. Macro-epidemiological approaches using electronic medical records
in suicide research are irreplaceable for their capability to account for multiple interactive risk factors,
moderators and confounders, and potential for immediate impact. The primary aims of the proposed
research project are to: 1) Estimate potentiating interactions between traumatic brain injury (TBI), a very
common condition in US Veterans, and inflammation-mediated medical conditions (IMCs: allergies,
infection, and autoimmune conditions), in predicting suicide in US Veterans. Our preliminary data
support hypothesizing synergistic interactions. 2) Estimate the suicide protective effect of sustained vs.
unsustained statin treatment 3) Identify demographic and clinical Veteran characteristics and
pharmacological statin features (dose, lipophilia, potency, duration) conducive to stronger attenuating
effects of statins on suicidal behavior. We will test these hypotheses on a Veterans Health Administration
(VHA) retrospective cohort (individuals with clinical encounters in VA Medical Centers nationwide
beginning in 2004 and followed for 13 years) including 5,446,318 Veterans with 28,749 suicides. The
Cox proportional hazard model will be applied to evaluate the interactions between TBI immune
mediated conditions , with Relative Excess Risk due to Interaction (RERI), the Attributable Proportion
(AP) due to interaction, and the Synergy Index (SI) to test synergism on an additive scale (Aim 1). A Cox
proportional hazard model will also be applied to testing risk attenuation with statins, with propensity
scoring for time-independent confounding and marginal structural Cox proportional hazards (Aim 2).
Finally, we will identify the demographic, clinical (diagnostic codes, medications, laboratory markers of
inflammation (e.g., white blood count) and pharmacological characteristic of Veterans expected to benefit
the most from sustained statin treatment using an aggregate machine learning approach (the
SuperLearner integrative methodology). Considering the high prevalence of TBI history and its ongoing
sequelae,( “a silent epidemic”) , especially in the VA, and confirming their synergistic interaction with
IMCs may contribute to developing suicide risk-attenuating interventions specifically for those
subpopulations. The PI’s preliminary data nested in Danish registers, our team’s piloting confirming
preliminarily a reduction in rates of psychiatric hospitalization (considered a proxy measure of suicide
risk) with statins in US Veterans diagnosed with schizophrenia or bipolar disorder and treated with
psychotropic medication (Appendix 4C), and our successful evaluation of potential heterogenous effects
of an alternative modifiable suicide risk using the specific machine learning algorithms proposed in this
project (Appendix 4B) support our hypotheses, integration, and purpose, and overall, project completion
capability. Using tailored repurposed medications, such as statins, targeting specifically molecular,
cellular and histological mechanisms directly implicated in suicidal behavior, to individuals at risk who
are identified by machine learning to potentially derive the greatest benefit from treatment , may provide
a much-needed breakthrough in suicide risk management and prevention.
他汀类药物除了具有代谢和心血管保护作用外,还具有可重复性
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TEODOR T POSTOLACHE其他文献
TEODOR T POSTOLACHE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TEODOR T POSTOLACHE', 18)}}的其他基金
Toxoplasma gondi, the kynurenine pathway, and suicidal behavior in veterans
弓形虫、犬尿氨酸途径和退伍军人的自杀行为
- 批准号:
9033416 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Seasonality of Mood: A Genome-Wide Association Study in the Old Order Amish
情绪的季节性:旧秩序阿米什人的全基因组关联研究
- 批准号:
8035847 - 财政年份:2010
- 资助金额:
-- - 项目类别:
LIGHT TREATMENT FOR WINTER SEASONAL AFFECTIVE DISORDER
冬季季节性情感障碍的光照治疗
- 批准号:
7951180 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Light Treatment for Winter-SAD: Prediction of Response by Immediate Improvement
冬季 SAD 的光照治疗:通过立即改善预测反应
- 批准号:
7496961 - 财政年份:2007
- 资助金额:
-- - 项目类别:
Light Treatment for Winter-SAD: Prediction of Response by Immediate Improvement
冬季 SAD 的光照治疗:通过立即改善预测反应
- 批准号:
7641108 - 财政年份:2007
- 资助金额:
-- - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
-- - 项目类别:
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
-- - 项目类别: